You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePropafenone
Accession NumberDB01182  (APRD00261)
TypeSmall Molecule
GroupsApproved
DescriptionAn antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. [PubChem]
Structure
Thumb
Synonyms
1-(2-(2-Hydroxy-3-(propylamino)propoxy)phenyl)-3-phenyl-1-propanone
2-(2'-Hydroxy-3'-propylaminopropoxy)-omega-phenylpropiophenone
Propafenona
Propafenonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Myl-propafenonetablet150 mgoralMylan Pharmaceuticals Ulc2002-03-08Not applicableCanada
Myl-propafenonetablet300 mgoralMylan Pharmaceuticals Ulc2002-03-08Not applicableCanada
Nu-propafenonetablet150 mgoralNu Pharm IncNot applicableNot applicableCanada
PMS-propafenonetablet300 mgoralPharmascience Inc2008-02-22Not applicableCanada
PMS-propafenonetablet150 mgoralPharmascience Inc2001-04-09Not applicableCanada
PMS-propafenonetablet300 mgoralPharmascience Inc2001-04-09Not applicableCanada
PMS-propafenonetablet150 mgoralPharmascience Inc2008-02-22Not applicableCanada
Propafenonetablet150 mgoralSanis Health Inc2010-02-16Not applicableCanada
Propafenonetablet300 mgoralSanis Health Inc2010-02-16Not applicableCanada
Propafenone Hydrochloride SRcapsule, extended release425 mg/1oralPrasco Laboratories2014-10-22Not applicableUs
Propafenone Hydrochloride SRcapsule, extended release225 mg/1oralPrasco Laboratories2014-10-22Not applicableUs
Propafenone Hydrochloride SRcapsule, extended release325 mg/1oralPrasco Laboratories2014-10-22Not applicableUs
Propafenone-150tablet150 mgoralPro Doc Limitee2008-03-072016-07-18Canada
Propafenone-300tablet300 mgoralPro Doc Limitee2009-05-262016-07-18Canada
Rythmoltablet, film coated150 mg/1oralGlaxo Smith Kline Llc2010-01-04Not applicableUs
Rythmoltablet150 mgoralBgp Pharma Ulc1988-12-31Not applicableCanada
Rythmoltablet, film coated225 mg/1oralGlaxo Smith Kline Llc2010-01-04Not applicableUs
Rythmoltablet300 mgoralBgp Pharma Ulc1988-12-31Not applicableCanada
Rythmol SRcapsule, extended release425 mg/1oralGlaxo Smith Kline Llc2011-03-17Not applicableUs
Rythmol SRcapsule, extended release225 mg/1oralGlaxo Smith Kline Llc2011-03-17Not applicableUs
Rythmol SRcapsule, extended release325 mg/1oralGlaxo Smith Kline Llc2011-03-17Not applicableUs
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-propafenonetablet150 mgoralApotex Inc2001-02-22Not applicableCanada
Apo-propafenonetablet300 mgoralApotex Inc2001-02-22Not applicableCanada
Propafenonecapsule, extended release325 mg/1oralRebel Distributors Corp2011-01-03Not applicableUs
Propafenone HCltablet, film coated150 mg/1oralActavis Pharma, Inc.2000-10-24Not applicableUs
Propafenone HCltablet, film coated150 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-10Not applicableUs
Propafenone HCltablet, film coated225 mg/1oralActavis Pharma, Inc.2000-10-24Not applicableUs
Propafenone HCltablet, film coated225 mg/1oralAvera Mc Kennan Hospital2015-10-01Not applicableUs
Propafenone HCltablet, film coated225 mg/1oralMc Kesson Packaging Services A Business Unit Of Mc Kesson Corporation2012-09-10Not applicableUs
Propafenone HCltablet, film coated150 mg/1oralAmerican Health Packaging2012-05-01Not applicableUs
Propafenone Hydrochloridetablet, film coated300 mg/1oralQualitest Pharmaceuticals2002-10-17Not applicableUs
Propafenone Hydrochloridetablet, coated150 mg/1oralANI Pharmaceuticals, Inc.2015-03-31Not applicableUs
Propafenone Hydrochloridecapsule, extended release225 mg/1oralAv Kare, Inc.2016-01-21Not applicableUs
Propafenone Hydrochloridetablet, film coated150 mg/1oralMutual Pharmaceutical Co., Inc.2001-11-29Not applicableUs
Propafenone Hydrochloridecapsule, extended release325 mg/1oralAmerican Health Packaging2015-03-31Not applicableUs
Propafenone Hydrochloridecapsule, extended release225 1/1oralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone Hydrochloridecapsule, extended release425 mg/1oralActavis Pharma, Inc.2015-10-15Not applicableUs
Propafenone Hydrochloridetablet, film coated225 mg/1oralPhysicians Total Care, Inc.2008-10-09Not applicableUs
Propafenone Hydrochloridecapsule, extended release425 mg/1oralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Propafenone Hydrochloridetablet, film coated150 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2002-10-17Not applicableUs
Propafenone Hydrochloridetablet, coated225 mg/1oralANI Pharmaceuticals, Inc.2015-03-31Not applicableUs
Propafenone Hydrochloridecapsule, extended release325 mg/1oralAv Kare, Inc.2016-01-21Not applicableUs
Propafenone Hydrochloridetablet, film coated225 mg/1oralMutual Pharmaceutical Co., Inc.2001-11-29Not applicableUs
Propafenone Hydrochloridecapsule, extended release325 mg/1oralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone Hydrochloridetablet, film coated150 mg/1oralCardinal Health2011-05-20Not applicableUs
Propafenone Hydrochloridetablet, film coated150 mg/1oralQualitest Pharmaceuticals2002-10-17Not applicableUs
Propafenone Hydrochloridetablet, coated300 mg/1oralANI Pharmaceuticals, Inc.2015-03-31Not applicableUs
Propafenone Hydrochloridecapsule, extended release425 mg/1oralAv Kare, Inc.2016-01-21Not applicableUs
Propafenone Hydrochloridecapsule, extended release225 mg/1oralActavis Pharma, Inc.2015-10-15Not applicableUs
Propafenone Hydrochloridetablet, film coated300 mg/1oralMutual Pharmaceutical Co., Inc.2001-11-29Not applicableUs
Propafenone Hydrochloridecapsule, extended release225 mg/1oralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Propafenone Hydrochloridecapsule, extended release425 mg/1oralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone Hydrochloridecapsule, extended release225 1/1oralAmerican Health Packaging2015-10-01Not applicableUs
Propafenone Hydrochloridetablet, film coated225 mg/1oralQualitest Pharmaceuticals2002-10-17Not applicableUs
Propafenone Hydrochloridecapsule, extended release225 mg/1oralPar Pharmaceutical, Inc.2011-01-03Not applicableUs
Propafenone Hydrochloridetablet, film coated150 mg/1oralbryant ranch prepack2002-10-17Not applicableUs
Propafenone Hydrochloridecapsule, extended release325 mg/1oralActavis Pharma, Inc.2015-10-15Not applicableUs
Propafenone Hydrochloridetablet, film coated150 mg/1oralPhysicians Total Care, Inc.2005-05-18Not applicableUs
Propafenone Hydrochloridecapsule, extended release325 mg/1oralGolden State Medical Supply, Inc.2015-09-15Not applicableUs
Propafenone Hydrochloridecapsule, extended release225 mg/1oralAmerican Health Packaging2014-10-20Not applicableUs
Propafenone Hydrochloridetablet, film coated150 mg/1oralMylan Institutional Inc.2003-02-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International BrandsNot Available
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Propafenone hydrochloride
34183-22-7
Thumb
  • InChI Key: XWIHRGFIPXWGEF-UHFFFAOYNA-N
  • Monoisotopic Mass: 377.175771474
  • Average Mass: 377.905
DBSALT000148
Categories
UNII68IQX3T69U
CAS number54063-53-5
WeightAverage: 341.444
Monoisotopic: 341.199093735
Chemical FormulaC21H27NO3
InChI KeyInChIKey=JWHAUXFOSRPERK-UHFFFAOYSA-N
InChI
InChI=1S/C21H27NO3/c1-2-14-22-15-18(23)16-25-21-11-7-6-10-19(21)20(24)13-12-17-8-4-3-5-9-17/h3-11,18,22-23H,2,12-16H2,1H3
IUPAC Name
1-{2-[2-hydroxy-3-(propylamino)propoxy]phenyl}-3-phenylpropan-1-one
SMILES
CCCNCC(O)COC1=CC=CC=C1C(=O)CCC1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as chalcones and dihydrochalcones. These are organic compounds containing 1,3-Diphenylpropenone (benzylideneacetophenone), ArCH=CH(=O)Ar,or its derivatives formed by substitution.
KingdomOrganic compounds
Super ClassPhenylpropanoids and polyketides
ClassLinear 1,3-diarylpropanoids
Sub ClassChalcones and dihydrochalcones
Direct ParentChalcones and dihydrochalcones
Alternative Parents
Substituents
  • Chalcone or dihydrochalcone
  • Butyrophenone
  • Acetophenone
  • Aryl alkyl ketone
  • Aryl ketone
  • Phenol ether
  • Benzoyl
  • Alkyl aryl ether
  • Benzenoid
  • Monocyclic benzene moiety
  • Secondary alcohol
  • Ketone
  • 1,2-aminoalcohol
  • Secondary amine
  • Ether
  • Secondary aliphatic amine
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic homomonocyclic compound
Molecular FrameworkAromatic homomonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationUsed to prolong the time to recurrence of paroxysmal atrial fibrillation/flutter (PAF) associated with disabling symptoms in patients without structural heart disease. Also used for the treatment of life-threatening documented ventricular arrhythmias, such as sustained ventricular tachycardia.
PharmacodynamicsPropafenone is a Class 1C antiarrhythmic drug with local anesthetic effects, and a direct stabilizing action on myocardial membranes. It is used in the treatment of atrial and ventricular arrhythmias. It works by slowing the influx of sodium ions into the cardiac muscle cells, causing a decrease in excitablity of the cells. Propafenone has local anesthetic activity approximately equal to procaine.
Mechanism of actionThe electrophysiological effect of propafenone manifests itself in a reduction of upstroke velocity (Phase 0) of the monophasic action potential. In Purkinje fibers, and to a lesser extent myocardial fibers, propafenone reduces the fast inward current carried by sodium ions, which is responsible for the drugs antiarrhythmic actions. Diastolic excitability threshold is increased and effective refractory period prolonged. Propafenone reduces spontaneous automaticity and depresses triggered activity. At very high concentrations in vitro, propafenone can inhibit the slow inward current carried by calcium but this calcium antagonist effect probably does not contribute to antiarrhythmic efficacy.
Related Articles
AbsorptionNearly completely absorbed following oral administration (90%). Systemic bioavailability ranges from 5 to 50%, due to significant first-pass metabolism. This wide range in systemic bioavailability is related to two factors: presence of food (food increases bioavailability) and dosage (bioavailability is 3.4% for a 150-mg tablet compared to 10.6% for a 300-mg tablet).
Volume of distribution
  • 252 L
Protein binding97%
Metabolism

Metabolized primarily in the liver where it is rapidly and extensively metabolized to two active metabolites, 5-hydroxypropafenone and N-depropylpropafenone. These metabolites have antiarrhythmic activity comparable to propafenone but are present in concentrations less than 25% of propafenone concentrations.

SubstrateEnzymesProduct
Propafenone
N-desalkylpropafenoneDetails
Propafenone
5-hydroxypropafenoneDetails
Propafenone
Not Available
N-depropylpropafenoneDetails
Route of eliminationApproximately 50% of propafenone metabolites are excreted in the urine following administration of immediate release tablets.
Half life2-10 hours
ClearanceNot Available
ToxicitySymptoms of propafenone overdose (usually most severe within the first 3 hours) may include convulsions (rarely), heartbeat irregularities, low blood pressure, and sleepiness.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.996
Blood Brain Barrier-0.958
Caco-2 permeable-0.5433
P-glycoprotein substrateSubstrate0.8548
P-glycoprotein inhibitor IInhibitor0.8565
P-glycoprotein inhibitor IIInhibitor0.874
Renal organic cation transporterNon-inhibitor0.7204
CYP450 2C9 substrateNon-substrate0.7897
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateNon-substrate0.5499
CYP450 1A2 substrateInhibitor0.9106
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorInhibitor0.8932
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorInhibitor0.7066
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8931
Ames testNon AMES toxic0.8446
CarcinogenicityNon-carcinogens0.8879
BiodegradationNot ready biodegradable0.803
Rat acute toxicity2.3795 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.5383
hERG inhibition (predictor II)Inhibitor0.8915
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Tabletoral150 mg
Tabletoral300 mg
Capsule, extended releaseoral225 1/1
Tablet, coatedoral150 mg/1
Tablet, coatedoral225 mg/1
Tablet, coatedoral300 mg/1
Tablet, film coatedoral300 mg/1
Tablet, film coatedoral150 mg/1
Tablet, film coatedoral225 mg/1
Capsule, extended releaseoral225 mg/1
Capsule, extended releaseoral325 mg/1
Capsule, extended releaseoral425 mg/1
Prices
Unit descriptionCostUnit
Rythmol SR 325 mg 12 Hour Capsule8.9USD capsule
Rythmol SR 425 mg 12 Hour Capsule8.9USD capsule
Rythmol sr 325 mg capsule8.56USD capsule
Rythmol sr 425 mg capsule8.56USD capsule
Rythmol SR 225 mg 12 Hour Capsule7.02USD capsule
Rythmol sr 225 mg capsule6.75USD capsule
Rythmol 225 mg tablet6.2USD tablet
Rythmol 300 mg tablet5.05USD tablet
Rythmol 150 mg tablet3.95USD tablet
Propafenone hcl 300 mg tablet3.03USD tablet
Propafenone hcl 225 mg tablet2.38USD tablet
Rythmol 300 mg Tablet2.09USD tablet
Propafenone hcl 150 mg tablet1.64USD tablet
Rythmol 150 mg Tablet1.18USD tablet
Apo-Propafenone 300 mg Tablet0.79USD tablet
Pms-Propafenone 300 mg Tablet0.79USD tablet
Apo-Propafenone 150 mg Tablet0.45USD tablet
Pms-Propafenone 150 mg Tablet0.45USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5681588 No1994-10-282014-10-28Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilitySlightly solubleNot Available
logP3.2Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00758 mg/mLALOGPS
logP3.1ALOGPS
logP3.54ChemAxon
logS-4.7ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.63ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area58.56 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity100.21 m3·mol-1ChemAxon
Polarizability39.75 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Helmut Lietz, “Preparation of propafenone.” U.S. Patent US4474986, issued May, 1974.

US4474986
General ReferencesNot Available
External Links
ATC CodesC01BC03
AHFS Codes
  • 24:04.04.12
PDB EntriesNot Available
FDA labelDownload (91.1 KB)
MSDSDownload (73.7 KB)
Interactions
Drug Interactions
Drug
AbirateroneThe serum concentration of Abiraterone can be increased when it is combined with Propafenone.
AcebutololThe serum concentration of Acebutolol can be increased when it is combined with Propafenone.
AcebutololAcebutolol may increase the bradycardic activities of Propafenone.
AcenocoumarolThe serum concentration of Acenocoumarol can be increased when it is combined with Propafenone.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Propafenone.
AcetyldigitoxinThe serum concentration of Acetyldigitoxin can be increased when it is combined with Propafenone.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Propafenone.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Propafenone.
AjmalinePropafenone may increase the arrhythmogenic activities of Ajmaline.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Propafenone.
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Propafenone.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Propafenone.
AlprenololThe serum concentration of Alprenolol can be increased when it is combined with Propafenone.
AmantadineAmantadine may increase the QTc-prolonging activities of Propafenone.
AmbrisentanThe serum concentration of Ambrisentan can be increased when it is combined with Propafenone.
AminophyllineThe serum concentration of Aminophylline can be increased when it is combined with Propafenone.
AmiodaronePropafenone may increase the arrhythmogenic activities of Amiodarone.
AmiodaroneThe risk or severity of adverse effects can be increased when Amiodarone is combined with Propafenone.
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Propafenone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Propafenone.
AmodiaquineThe serum concentration of Amodiaquine can be increased when it is combined with Propafenone.
AmoxapineAmoxapine may increase the QTc-prolonging activities of Propafenone.
AnagrelidePropafenone may increase the QTc-prolonging activities of Anagrelide.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Propafenone.
ApomorphineApomorphine may increase the QTc-prolonging activities of Propafenone.
AprepitantThe serum concentration of Propafenone can be increased when it is combined with Aprepitant.
ArformoterolArformoterol may increase the QTc-prolonging activities of Propafenone.
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Propafenone.
AripiprazoleAripiprazole may increase the QTc-prolonging activities of Propafenone.
ArotinololThe serum concentration of Arotinolol can be increased when it is combined with Propafenone.
Arsenic trioxidePropafenone may increase the QTc-prolonging activities of Arsenic trioxide.
ArtemetherPropafenone may increase the QTc-prolonging activities of Artemether.
ArtemetherThe metabolism of Propafenone can be decreased when combined with Artemether.
AsenapinePropafenone may increase the QTc-prolonging activities of Asenapine.
AtazanavirThe serum concentration of Propafenone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Atenolol can be increased when it is combined with Propafenone.
AtenololAtenolol may increase the bradycardic activities of Propafenone.
AtomoxetineThe serum concentration of Propafenone can be increased when it is combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Propafenone.
AzithromycinPropafenone may increase the QTc-prolonging activities of Azithromycin.
AzithromycinThe metabolism of Propafenone can be decreased when combined with Azithromycin.
BedaquilinePropafenone may increase the QTc-prolonging activities of Bedaquiline.
BefunololThe serum concentration of Befunolol can be increased when it is combined with Propafenone.
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Propafenone.
BeractantPropafenone may increase the bradycardic activities of Beractant.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Propafenone.
BetaxololThe serum concentration of Betaxolol can be increased when it is combined with Propafenone.
BetaxololBetaxolol may increase the bradycardic activities of Propafenone.
BevantololThe serum concentration of Bevantolol can be increased when it is combined with Propafenone.
BexaroteneThe serum concentration of Propafenone can be decreased when it is combined with Bexarotene.
BisoprololThe serum concentration of Bisoprolol can be increased when it is combined with Propafenone.
BisoprololBisoprolol may increase the bradycardic activities of Propafenone.
BoceprevirThe serum concentration of Propafenone can be increased when it is combined with Boceprevir.
BopindololThe serum concentration of Bopindolol can be increased when it is combined with Propafenone.
BortezomibThe serum concentration of Propafenone can be increased when it is combined with Bortezomib.
BosentanThe serum concentration of Propafenone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Propafenone.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone.
BretyliumBretylium may increase the bradycardic activities of Propafenone.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Propafenone.
BufuralolThe serum concentration of Bufuralol can be increased when it is combined with Propafenone.
BupranololThe serum concentration of Bupranolol can be increased when it is combined with Propafenone.
BupropionThe serum concentration of Propafenone can be increased when it is combined with Bupropion.
BuserelinBuserelin may increase the QTc-prolonging activities of Propafenone.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Propafenone.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Propafenone.
CaffeineThe metabolism of Propafenone can be decreased when combined with Caffeine.
CalfactantPropafenone may increase the bradycardic activities of Calfactant.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Propafenone.
CanagliflozinThe serum concentration of Canagliflozin can be increased when it is combined with Propafenone.
CarbamazepineThe serum concentration of Propafenone can be decreased when it is combined with Carbamazepine.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Propafenone.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Propafenone.
CarteololThe serum concentration of Carteolol can be increased when it is combined with Propafenone.
CarteololCarteolol may increase the bradycardic activities of Propafenone.
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Propafenone.
CarvedilolCarvedilol may increase the bradycardic activities of Propafenone.
CelecoxibThe serum concentration of Celecoxib can be increased when it is combined with Propafenone.
CelecoxibThe metabolism of Propafenone can be decreased when combined with Celecoxib.
CeliprololThe serum concentration of Celiprolol can be increased when it is combined with Propafenone.
CeritinibPropafenone may increase the bradycardic activities of Ceritinib.
CeritinibThe serum concentration of Propafenone can be increased when it is combined with Ceritinib.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Propafenone.
ChloroquineThe serum concentration of Chloroquine can be increased when it is combined with Propafenone.
ChloroquineThe metabolism of Propafenone can be decreased when combined with Chloroquine.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Propafenone.
ChlorpromazineThe metabolism of Propafenone can be decreased when combined with Chlorpromazine.
CholecalciferolThe serum concentration of Cholecalciferol can be increased when it is combined with Propafenone.
CholecalciferolThe metabolism of Propafenone can be decreased when combined with Cholecalciferol.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Propafenone.
CinacalcetThe serum concentration of Propafenone can be increased when it is combined with Cinacalcet.
CiprofloxacinCiprofloxacin may increase the QTc-prolonging activities of Propafenone.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Propafenone.
CisapridePropafenone may increase the QTc-prolonging activities of Cisapride.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Propafenone.
CitalopramPropafenone may increase the QTc-prolonging activities of Citalopram.
CitalopramThe metabolism of Propafenone can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Propafenone can be increased when it is combined with Clarithromycin.
ClemastineThe serum concentration of Propafenone can be increased when it is combined with Clemastine.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Propafenone.
ClobazamThe metabolism of Propafenone can be decreased when combined with Clobazam.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Propafenone.
ClomipramineThe serum concentration of Clomipramine can be increased when it is combined with Propafenone.
ClomipramineClomipramine may increase the QTc-prolonging activities of Propafenone.
ClonidineThe serum concentration of Clonidine can be increased when it is combined with Propafenone.
ClonidineClonidine may increase the bradycardic activities of Propafenone.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Propafenone.
ClotrimazoleThe serum concentration of Propafenone can be increased when it is combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Propafenone.
ClozapineThe metabolism of Propafenone can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Propafenone can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Propafenone.
CocaineThe serum concentration of Propafenone can be increased when it is combined with Cocaine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Propafenone.
ConivaptanThe serum concentration of Propafenone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Propafenone.
CrizotinibThe serum concentration of Propafenone can be increased when it is combined with Crizotinib.
CyclosporineThe serum concentration of Propafenone can be increased when it is combined with Cyclosporine.
Cyproterone acetateThe serum concentration of Propafenone can be decreased when it is combined with Cyproterone acetate.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Propafenone.
DabrafenibDabrafenib may increase the QTc-prolonging activities of Propafenone.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Propafenone.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Propafenone.
DapagliflozinThe serum concentration of Dapagliflozin can be increased when it is combined with Propafenone.
DarifenacinThe serum concentration of Darifenacin can be increased when it is combined with Propafenone.
DarifenacinThe metabolism of Propafenone can be decreased when combined with Darifenacin.
DarunavirThe serum concentration of Propafenone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Propafenone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Propafenone.
DebrisoquinThe serum concentration of Debrisoquin can be increased when it is combined with Propafenone.
DeferasiroxThe serum concentration of Propafenone can be decreased when it is combined with Deferasirox.
DegarelixDegarelix may increase the QTc-prolonging activities of Propafenone.
DelavirdineThe serum concentration of Propafenone can be increased when it is combined with Delavirdine.
DesfluraneDesflurane may increase the QTc-prolonging activities of Propafenone.
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Propafenone.
DesipramineDesipramine may increase the QTc-prolonging activities of Propafenone.
DeslanosideThe serum concentration of Deslanoside can be increased when it is combined with Propafenone.
DexamethasoneThe serum concentration of Propafenone can be decreased when it is combined with Dexamethasone.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Propafenone.
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Propafenone.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Propafenone.
DicoumarolThe serum concentration of Dicoumarol can be increased when it is combined with Propafenone.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Propafenone.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Propafenone.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Propafenone.
DigoxinDigoxin may increase the bradycardic activities of Propafenone.
DihydroergotamineThe serum concentration of Propafenone can be increased when it is combined with Dihydroergotamine.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Propafenone.
DiltiazemThe serum concentration of Propafenone can be increased when it is combined with Diltiazem.
DiphenhydramineThe serum concentration of Diphenhydramine can be increased when it is combined with Propafenone.
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Propafenone.
DipyridamoleThe serum concentration of Dipyridamole can be increased when it is combined with Propafenone.
DisopyramidePropafenone may increase the arrhythmogenic activities of Disopyramide.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Propafenone.
DofetilidePropafenone may increase the arrhythmogenic activities of Dofetilide.
DolasetronDolasetron may increase the QTc-prolonging activities of Propafenone.
DomperidonePropafenone may increase the QTc-prolonging activities of Domperidone.
DonepezilDonepezil may increase the bradycardic activities of Propafenone.
DoxepinDoxepin may increase the QTc-prolonging activities of Propafenone.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Propafenone.
DoxycyclineThe serum concentration of Propafenone can be increased when it is combined with Doxycycline.
DronedaroneThe serum concentration of Propafenone can be increased when it is combined with Dronedarone.
DronedaronePropafenone may increase the arrhythmogenic activities of Dronedarone.
DroperidolDroperidol may increase the QTc-prolonging activities of Propafenone.
DuloxetineThe serum concentration of Duloxetine can be increased when it is combined with Propafenone.
DuloxetineThe metabolism of Propafenone can be decreased when combined with Duloxetine.
DyphyllineThe serum concentration of Dyphylline can be increased when it is combined with Propafenone.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Propafenone.
EfavirenzThe serum concentration of Propafenone can be decreased when it is combined with Efavirenz.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Propafenone.
EliglustatPropafenone may increase the QTc-prolonging activities of Eliglustat.
EliglustatThe metabolism of Propafenone can be decreased when combined with Eliglustat.
EnzalutamideThe serum concentration of Propafenone can be decreased when it is combined with Enzalutamide.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Propafenone.
EribulinEribulin may increase the QTc-prolonging activities of Propafenone.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Propafenone.
ErythromycinThe serum concentration of Propafenone can be increased when it is combined with Erythromycin.
EscitalopramPropafenone may increase the QTc-prolonging activities of Escitalopram.
Eslicarbazepine acetateThe serum concentration of Propafenone can be decreased when it is combined with Eslicarbazepine acetate.
EsmololThe serum concentration of Esmolol can be increased when it is combined with Propafenone.
EsmololEsmolol may increase the bradycardic activities of Propafenone.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Propafenone.
EstriolThe serum concentration of Estriol can be increased when it is combined with Propafenone.
EstroneThe serum concentration of Estrone can be increased when it is combined with Propafenone.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Propafenone.
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be increased when it is combined with Propafenone.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Propafenone.
EtravirineThe serum concentration of Propafenone can be decreased when it is combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Propafenone.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Propafenone.
EzogabineEzogabine may increase the QTc-prolonging activities of Propafenone.
FamotidineFamotidine may increase the QTc-prolonging activities of Propafenone.
FelbamateFelbamate may increase the QTc-prolonging activities of Propafenone.
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Propafenone.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Propafenone.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Propafenone.
FingolimodFingolimod may increase the QTc-prolonging activities of Propafenone.
FingolimodPropafenone may increase the bradycardic activities of Fingolimod.
FlecainidePropafenone may increase the QTc-prolonging activities of Flecainide.
FluconazoleThe serum concentration of Propafenone can be increased when it is combined with Fluconazole.
FluoxetinePropafenone may increase the QTc-prolonging activities of Fluoxetine.
FluoxetineThe serum concentration of Propafenone can be increased when it is combined with Fluoxetine.
FlupentixolPropafenone may increase the QTc-prolonging activities of Flupentixol.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Propafenone.
FluvoxamineThe serum concentration of Propafenone can be increased when it is combined with Fluvoxamine.
FormoterolFormoterol may increase the QTc-prolonging activities of Propafenone.
FosamprenavirThe serum concentration of Propafenone can be increased when it is combined with Fosamprenavir.
FosaprepitantThe serum concentration of Propafenone can be increased when it is combined with Fosaprepitant.
FoscarnetFoscarnet may increase the QTc-prolonging activities of Propafenone.
FosphenytoinThe serum concentration of Propafenone can be decreased when it is combined with Fosphenytoin.
Fusidic AcidThe serum concentration of Propafenone can be increased when it is combined with Fusidic Acid.
Gadobenic acidGadobenic acid may increase the QTc-prolonging activities of Propafenone.
GalantamineGalantamine may increase the QTc-prolonging activities of Propafenone.
GalantaminePropafenone may increase the bradycardic activities of Galantamine.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Propafenone.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Propafenone.
GemifloxacinGemifloxacin may increase the QTc-prolonging activities of Propafenone.
GoserelinGoserelin may increase the QTc-prolonging activities of Propafenone.
GranisetronGranisetron may increase the QTc-prolonging activities of Propafenone.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Propafenone.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Propafenone.
GuanfacineGuanfacine may increase the bradycardic activities of Propafenone.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Propafenone.
HaloperidolThe metabolism of Propafenone can be decreased when combined with Haloperidol.
HistrelinHistrelin may increase the QTc-prolonging activities of Propafenone.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Propafenone.
HydroxyzineHydroxyzine may increase the QTc-prolonging activities of Propafenone.
IbandronateIbandronate may increase the QTc-prolonging activities of Propafenone.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Propafenone.
IbutilidePropafenone may increase the arrhythmogenic activities of Ibutilide.
IdelalisibThe serum concentration of Propafenone can be increased when it is combined with Idelalisib.
IloperidonePropafenone may increase the QTc-prolonging activities of Iloperidone.
ImatinibThe serum concentration of Propafenone can be increased when it is combined with Imatinib.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Propafenone.
ImipramineImipramine may increase the QTc-prolonging activities of Propafenone.
IndacaterolIndacaterol may increase the QTc-prolonging activities of Propafenone.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Propafenone.
IndapamideIndapamide may increase the QTc-prolonging activities of Propafenone.
IndenololThe serum concentration of Indenolol can be increased when it is combined with Propafenone.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Propafenone.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Propafenone.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Propafenone.
IsavuconazoniumThe serum concentration of Propafenone can be increased when it is combined with Isavuconazonium.
IsofluraneIsoflurane may increase the QTc-prolonging activities of Propafenone.
IsoniazidThe serum concentration of Isoniazid can be increased when it is combined with Propafenone.
IsoniazidThe metabolism of Propafenone can be decreased when combined with Isoniazid.
IsradipineThe serum concentration of Propafenone can be increased when it is combined with Isradipine.
ItraconazoleThe serum concentration of Propafenone can be increased when it is combined with Itraconazole.
IvabradineIvabradine may increase the QTc-prolonging activities of Propafenone.
IvabradinePropafenone may increase the bradycardic activities of Ivabradine.
IvacaftorThe serum concentration of Propafenone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Propafenone.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Propafenone.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Propafenone.
LabetalolThe serum concentration of Labetalol can be increased when it is combined with Propafenone.
LabetalolLabetalol may increase the bradycardic activities of Propafenone.
LacosamidePropafenone may increase the atrioventricular blocking (AV block) activities of Lacosamide.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Propafenone.
LamotrigineThe serum concentration of Lamotrigine can be increased when it is combined with Propafenone.
LanreotidePropafenone may increase the bradycardic activities of Lanreotide.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Propafenone.
LapatinibLapatinib may increase the QTc-prolonging activities of Propafenone.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Propafenone.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Propafenone.
LenvatinibLenvatinib may increase the QTc-prolonging activities of Propafenone.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Propafenone.
LeuprolideLeuprolide may increase the QTc-prolonging activities of Propafenone.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Propafenone.
LevobunololThe serum concentration of Levobunolol can be increased when it is combined with Propafenone.
LevobunololLevobunolol may increase the bradycardic activities of Propafenone.
LevofloxacinLevofloxacin may increase the QTc-prolonging activities of Propafenone.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Propafenone.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Propafenone.
LidocaineThe metabolism of Propafenone can be decreased when combined with Lidocaine.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Propafenone.
LithiumLithium may increase the QTc-prolonging activities of Propafenone.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Propafenone.
LopinavirThe serum concentration of Propafenone can be increased when it is combined with Lopinavir.
LopinavirPropafenone may increase the QTc-prolonging activities of Lopinavir.
LorcaserinThe serum concentration of Lorcaserin can be increased when it is combined with Propafenone.
LorcaserinThe metabolism of Propafenone can be decreased when combined with Lorcaserin.
LosartanThe serum concentration of Losartan can be increased when it is combined with Propafenone.
LovastatinThe serum concentration of Propafenone can be increased when it is combined with Lovastatin.
LucinactantPropafenone may increase the bradycardic activities of Lucinactant.
LuliconazoleThe serum concentration of Propafenone can be increased when it is combined with Luliconazole.
LumefantrinePropafenone may increase the QTc-prolonging activities of Lumefantrine.
LumefantrineThe metabolism of Propafenone can be decreased when combined with Lumefantrine.
MannitolThe serum concentration of Mannitol can be increased when it is combined with Propafenone.
MaprotilineMaprotiline may increase the QTc-prolonging activities of Propafenone.
MefloquineMefloquine may increase the QTc-prolonging activities of Propafenone.
MethadoneThe serum concentration of Methadone can be increased when it is combined with Propafenone.
MethadoneThe metabolism of Propafenone can be decreased when combined with Methadone.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Propafenone.
MethotrimeprazineThe serum concentration of Propafenone can be increased when it is combined with Methotrimeprazine.
MethyldopaMethyldopa may increase the bradycardic activities of Propafenone.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Propafenone.
MetipranololThe serum concentration of Metipranolol can be increased when it is combined with Propafenone.
MetipranololMetipranolol may increase the bradycardic activities of Propafenone.
MetoclopramideMetoclopramide may increase the QTc-prolonging activities of Propafenone.
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Propafenone.
MetoprololMetoprolol may increase the bradycardic activities of Propafenone.
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Propafenone.
MexiletineThe metabolism of Propafenone can be decreased when combined with Mexiletine.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Propafenone.
MifepristoneMifepristone may increase the QTc-prolonging activities of Propafenone.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Propafenone.
MirtazapineMirtazapine may increase the QTc-prolonging activities of Propafenone.
MitotaneThe serum concentration of Propafenone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Propafenone.
ModafinilThe serum concentration of Propafenone can be decreased when it is combined with Modafinil.
MoexiprilMoexipril may increase the QTc-prolonging activities of Propafenone.
MorphineThe serum concentration of Morphine can be increased when it is combined with Propafenone.
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Propafenone.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Propafenone.
NadololThe serum concentration of Nadolol can be increased when it is combined with Propafenone.
NadololNadolol may increase the bradycardic activities of Propafenone.
NafcillinThe serum concentration of Propafenone can be decreased when it is combined with Nafcillin.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Propafenone.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Propafenone.
NebivololPropafenone may increase the bradycardic activities of Nebivolol.
NefazodoneThe serum concentration of Propafenone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Propafenone can be increased when it is combined with Nelfinavir.
NetupitantThe serum concentration of Propafenone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Propafenone can be increased when it is combined with Nevirapine.
NicardipineThe serum concentration of Nicardipine can be increased when it is combined with Propafenone.
NicardipineNicardipine may increase the QTc-prolonging activities of Propafenone.
NifedipineThe serum concentration of Nifedipine can be increased when it is combined with Propafenone.
NilotinibThe serum concentration of Propafenone can be increased when it is combined with Nilotinib.
NilotinibPropafenone may increase the QTc-prolonging activities of Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Propafenone.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Propafenone.
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Propafenone.
NortriptylineNortriptyline may increase the QTc-prolonging activities of Propafenone.
OctreotideOctreotide may increase the QTc-prolonging activities of Propafenone.
OctreotidePropafenone may increase the bradycardic activities of Octreotide.
OfloxacinOfloxacin may increase the QTc-prolonging activities of Propafenone.
OlanzapineOlanzapine may increase the QTc-prolonging activities of Propafenone.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Propafenone.
OlaparibThe serum concentration of Propafenone can be increased when it is combined with Olaparib.
OlodaterolOlodaterol may increase the QTc-prolonging activities of Propafenone.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Propafenone.
OndansetronOndansetron may increase the QTc-prolonging activities of Propafenone.
OrlistatThe serum concentration of Propafenone can be decreased when it is combined with Orlistat.
OsimertinibThe serum concentration of Propafenone can be increased when it is combined with Osimertinib.
OuabainThe serum concentration of Ouabain can be increased when it is combined with Propafenone.
OxprenololThe serum concentration of Oxprenolol can be increased when it is combined with Propafenone.
OxytocinOxytocin may increase the QTc-prolonging activities of Propafenone.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Propafenone.
PalbociclibThe serum concentration of Propafenone can be increased when it is combined with Palbociclib.
PaliperidonePropafenone may increase the QTc-prolonging activities of Paliperidone.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Propafenone.
PanobinostatThe metabolism of Propafenone can be decreased when combined with Panobinostat.
ParoxetineThe serum concentration of Propafenone can be increased when it is combined with Paroxetine.
PasireotidePasireotide may increase the QTc-prolonging activities of Propafenone.
PasireotidePropafenone may increase the bradycardic activities of Pasireotide.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Propafenone.
PazopanibPazopanib may increase the QTc-prolonging activities of Propafenone.
Peginterferon alfa-2bThe serum concentration of Propafenone can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololThe serum concentration of Penbutolol can be increased when it is combined with Propafenone.
PenbutololPenbutolol may increase the bradycardic activities of Propafenone.
PentamidinePentamidine may increase the QTc-prolonging activities of Propafenone.
PentobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Pentobarbital.
PerflutrenPerflutren may increase the QTc-prolonging activities of Propafenone.
PhenindioneThe serum concentration of Phenindione can be increased when it is combined with Propafenone.
PhenobarbitalThe serum concentration of Propafenone can be decreased when it is combined with Phenobarbital.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Propafenone.
PhenprocoumonThe serum concentration of Phenprocoumon can be increased when it is combined with Propafenone.
PhenytoinThe serum concentration of Propafenone can be decreased when it is combined with Phenytoin.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Propafenone.
PimozidePropafenone may increase the QTc-prolonging activities of Pimozide.
PindololThe serum concentration of Pindolol can be increased when it is combined with Propafenone.
PindololPindolol may increase the bradycardic activities of Propafenone.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Propafenone.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Propafenone.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Propafenone.
Poractant alfaPropafenone may increase the bradycardic activities of Poractant alfa.
PosaconazoleThe serum concentration of Propafenone can be increased when it is combined with Posaconazole.
PractololThe serum concentration of Practolol can be increased when it is combined with Propafenone.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Propafenone.
PrazosinThe serum concentration of Prazosin can be increased when it is combined with Propafenone.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Propafenone.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Propafenone.
PrimaquinePrimaquine may increase the QTc-prolonging activities of Propafenone.
PrimidoneThe serum concentration of Propafenone can be decreased when it is combined with Primidone.
ProcainamidePropafenone may increase the arrhythmogenic activities of Procainamide.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Propafenone.
PromazineThe serum concentration of Promazine can be increased when it is combined with Propafenone.
PromazineThe metabolism of Propafenone can be decreased when combined with Promazine.
PromethazinePromethazine may increase the QTc-prolonging activities of Propafenone.
PropofolPropofol may increase the QTc-prolonging activities of Propafenone.
PropranololThe serum concentration of Propranolol can be increased when it is combined with Propafenone.
PropranololPropranolol may increase the bradycardic activities of Propafenone.
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Propafenone.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Propafenone.
QuetiapinePropafenone may increase the QTc-prolonging activities of Quetiapine.
QuinidinePropafenone may increase the arrhythmogenic activities of Quinidine.
QuinidineQuinidine may increase the QTc-prolonging activities of Propafenone.
QuininePropafenone may increase the QTc-prolonging activities of Quinine.
QuinineThe metabolism of Propafenone can be decreased when combined with Quinine.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Propafenone.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Propafenone.
ReserpineThe serum concentration of Reserpine can be increased when it is combined with Propafenone.
RifabutinThe serum concentration of Propafenone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Propafenone can be decreased when it is combined with Rifampicin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Propafenone.
RifapentineThe serum concentration of Propafenone can be decreased when it is combined with Rifapentine.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Propafenone.
RilpivirineRilpivirine may increase the QTc-prolonging activities of Propafenone.
RisperidoneRisperidone may increase the QTc-prolonging activities of Propafenone.
RisperidoneThe serum concentration of Risperidone can be increased when it is combined with Propafenone.
RitonavirThe serum concentration of Propafenone can be increased when it is combined with Ritonavir.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Propafenone.
RivastigmineRivastigmine may increase the bradycardic activities of Propafenone.
RolapitantThe serum concentration of Rolapitant can be increased when it is combined with Propafenone.
RolapitantThe metabolism of Propafenone can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Propafenone.
RopiniroleThe serum concentration of Ropinirole can be increased when it is combined with Propafenone.
RopiniroleThe metabolism of Propafenone can be decreased when combined with Ropinirole.
RuxolitinibRuxolitinib may increase the bradycardic activities of Propafenone.
SalbutamolSalbutamol may increase the QTc-prolonging activities of Propafenone.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Propafenone.
SalmeterolSalmeterol may increase the QTc-prolonging activities of Propafenone.
SaquinavirSaquinavir may increase the arrhythmogenic activities of Propafenone.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Propafenone.
SelexipagThe serum concentration of Selexipag can be increased when it is combined with Propafenone.
SertralineThe serum concentration of Sertraline can be increased when it is combined with Propafenone.
SertralineSertraline may increase the QTc-prolonging activities of Propafenone.
SevofluraneSevoflurane may increase the QTc-prolonging activities of Propafenone.
SildenafilThe serum concentration of Propafenone can be increased when it is combined with Sildenafil.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Propafenone.
SiltuximabThe serum concentration of Propafenone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Propafenone can be increased when it is combined with Simeprevir.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Propafenone.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Propafenone.
SolifenacinSolifenacin may increase the QTc-prolonging activities of Propafenone.
SorafenibSorafenib may increase the QTc-prolonging activities of Propafenone.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Propafenone.
SotalolPropafenone may increase the QTc-prolonging activities of Sotalol.
SotalolSotalol may increase the bradycardic activities of Propafenone.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Propafenone.
SparteinePropafenone may increase the arrhythmogenic activities of Sparteine.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Propafenone.
St. John's WortThe serum concentration of Propafenone can be decreased when it is combined with St. John's Wort.
StiripentolThe serum concentration of Propafenone can be increased when it is combined with Stiripentol.
SufentanilSufentanil may increase the bradycardic activities of Propafenone.
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Propafenone.
SulfisoxazoleThe serum concentration of Propafenone can be increased when it is combined with Sulfisoxazole.
SulfisoxazolePropafenone may increase the QTc-prolonging activities of Sulfisoxazole.
SunitinibSunitinib may increase the QTc-prolonging activities of Propafenone.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Propafenone.
TamoxifenTamoxifen may increase the QTc-prolonging activities of Propafenone.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Propafenone.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Propafenone.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Propafenone.
TedisamilPropafenone may increase the arrhythmogenic activities of Tedisamil.
TelaprevirThe serum concentration of Propafenone can be increased when it is combined with Telaprevir.
TelavancinPropafenone may increase the QTc-prolonging activities of Telavancin.
TelithromycinThe serum concentration of Propafenone can be increased when it is combined with Telithromycin.
TelithromycinPropafenone may increase the QTc-prolonging activities of Telithromycin.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Propafenone.
TenofovirThe metabolism of Propafenone can be decreased when combined with Tenofovir.
TerbinafineThe serum concentration of Propafenone can be increased when it is combined with Terbinafine.
TerbutalineTerbutaline may increase the QTc-prolonging activities of Propafenone.
TeriflunomideThe serum concentration of Propafenone can be decreased when it is combined with Teriflunomide.
TetrabenazinePropafenone may increase the QTc-prolonging activities of Tetrabenazine.
TheophyllineThe serum concentration of Theophylline can be increased when it is combined with Propafenone.
TheophyllineThe metabolism of Propafenone can be decreased when combined with Theophylline.
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Propafenone.
ThiothixeneThiothixene may increase the QTc-prolonging activities of Propafenone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Propafenone.
TiclopidineThe serum concentration of Propafenone can be increased when it is combined with Ticlopidine.
TimololThe serum concentration of Timolol can be increased when it is combined with Propafenone.
TimololTimolol may increase the bradycardic activities of Propafenone.
TipranavirThe serum concentration of Propafenone can be increased when it is combined with Tipranavir.
TizanidineTizanidine may increase the QTc-prolonging activities of Propafenone.
TizanidinePropafenone may increase the bradycardic activities of Tizanidine.
TocilizumabThe serum concentration of Propafenone can be decreased when it is combined with Tocilizumab.
TofacitinibTofacitinib may increase the bradycardic activities of Propafenone.
TolterodineTolterodine may increase the QTc-prolonging activities of Propafenone.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Propafenone.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Propafenone.
ToremifenePropafenone may increase the QTc-prolonging activities of Toremifene.
TranylcypromineThe serum concentration of Tranylcypromine can be increased when it is combined with Propafenone.
TranylcypromineThe metabolism of Propafenone can be decreased when combined with Tranylcypromine.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Propafenone.
TrazodoneTrazodone may increase the QTc-prolonging activities of Propafenone.
TreprostinilTreprostinil may increase the QTc-prolonging activities of Propafenone.
TrimethoprimTrimethoprim may increase the QTc-prolonging activities of Propafenone.
TrimipramineTrimipramine may increase the QTc-prolonging activities of Propafenone.
TriptorelinTriptorelin may increase the QTc-prolonging activities of Propafenone.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Propafenone.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Propafenone.
VandetanibPropafenone may increase the QTc-prolonging activities of Vandetanib.
VardenafilVardenafil may increase the QTc-prolonging activities of Propafenone.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Propafenone.
VemurafenibThe serum concentration of Propafenone can be increased when it is combined with Vemurafenib.
VemurafenibPropafenone may increase the QTc-prolonging activities of Vemurafenib.
VenlafaxineThe serum concentration of Propafenone can be increased when it is combined with Venlafaxine.
VerapamilThe serum concentration of Propafenone can be increased when it is combined with Verapamil.
VilanterolVilanterol may increase the QTc-prolonging activities of Propafenone.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Propafenone.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Propafenone.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Propafenone.
VoriconazoleThe serum concentration of Propafenone can be increased when it is combined with Voriconazole.
VorinostatVorinostat may increase the QTc-prolonging activities of Propafenone.
WarfarinThe serum concentration of Warfarin can be increased when it is combined with Propafenone.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Propafenone.
ZiprasidoneThe serum concentration of Propafenone can be increased when it is combined with Ziprasidone.
ZiprasidonePropafenone may increase the QTc-prolonging activities of Ziprasidone.
ZuclopenthixolPropafenone may increase the QTc-prolonging activities of Zuclopenthixol.
Food Interactions
  • Always take at the same time in regard to meals.
  • Grapefruit and grapefruit juice should be avoided throughout treatment. Grapefruit can increase serum levels of this product.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated sodium channel activity involved in sa node cell action potential
Specific Function:
This protein mediates the voltage-dependent sodium ion permeability of excitable membranes. Assuming opened or closed conformations in response to the voltage difference across the membrane, the protein forms a sodium-selective channel through which Na(+) ions may pass in accordance with their electrochemical gradient. It is a tetrodotoxin-resistant Na(+) channel isoform. This channel is respon...
Gene Name:
SCN5A
Uniprot ID:
Q14524
Molecular Weight:
226937.475 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Mergenthaler J, Haverkamp W, Huttenhofer A, Skryabin BV, Musshoff U, Borggrefe M, Speckmann EJ, Breithardt G, Madeja M: Blocking effects of the antiarrhythmic drug propafenone on the HERG potassium channel. Naunyn Schmiedebergs Arch Pharmacol. 2001 Apr;363(4):472-80. [PubMed:11330342 ]
  2. Arias C, Gonzalez T, Moreno I, Caballero R, Delpon E, Tamargo J, Valenzuela C: Effects of propafenone and its main metabolite, 5-hydroxypropafenone, on HERG channels. Cardiovasc Res. 2003 Mar;57(3):660-9. [PubMed:12618228 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Botsch S, Gautier JC, Beaune P, Eichelbaum M, Kroemer HK: Identification and characterization of the cytochrome P450 enzymes involved in N-dealkylation of propafenone: molecular base for interaction potential and variable disposition of active metabolites. Mol Pharmacol. 1993 Jan;43(1):120-6. [PubMed:8423765 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. In the epoxidation of arachidonic acid it generates only 14,15- and 11,12-cis-epoxyeicosatrienoic acids. It is the principal enzyme...
Gene Name:
CYP2C8
Uniprot ID:
P10632
Molecular Weight:
55824.275 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Schmid D, Ecker G, Kopp S, Hitzler M, Chiba P: Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements. Biochem Pharmacol. 1999 Nov 1;58(9):1447-56. [PubMed:10513988 ]
  2. Bachmakov I, Rekersbrink S, Hofmann U, Eichelbaum M, Fromm MF: Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein. Naunyn Schmiedebergs Arch Pharmacol. 2005 Mar;371(3):195-201. Epub 2005 Apr 15. [PubMed:15900513 ]
  3. Singh P, Paul K: Studies of interactions between uracil-based hybrid molecules and P-glycoprotein--search for multidrug resistance modulators. Bioorg Med Chem. 2006 Nov 1;14(21):7183-6. Epub 2006 Jul 14. [PubMed:16843673 ]
  4. Woodland C, Verjee Z, Giesbrecht E, Koren G, Ito S: The digoxin-propafenone interaction: characterization of a mechanism using renal tubular cell monolayers. J Pharmacol Exp Ther. 1997 Oct;283(1):39-45. [PubMed:9336306 ]
  5. Tmej C, Chiba P, Huber M, Richter E, Hitzler M, Schaper KJ, Ecker G: A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance. Arch Pharm (Weinheim). 1998 Jul-Aug;331(7-8):233-40. [PubMed:9747179 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23